Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis

CompletedOBSERVATIONAL
Enrollment

307

Participants

Timeline

Start Date

March 10, 2021

Primary Completion Date

December 23, 2023

Study Completion Date

December 23, 2023

Conditions
Invasive AspergillosisMucormycosis
Interventions
DRUG

Isavuconazole

antifungal agent

Trial Locations (16)

10126

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Turin

28041

Hospital Universitario 12 de Octubre, Madrid

39011

Hospital Universitario Marques de Valdecilla, Santander

50009

University Hospital Miguel Servet, Zaragoza

50937

University Hospital of Cologne, Cologne

59000

Hôpital Huriez CHU de Lille, Lille

60590

Universitätsklinik Frankfurt, Frankfurt

67033

Institut de Cancérologie, Strasbourg

75015

Paris University, Paris

81675

Klinikum rechts der Isar Technische Universität München, Munich

87042

CHU de Limoges, Limoges

89081

Comprehensive Cancer Center Ulm (CCCU), Ulm

08035

Vall d'Hebron University Hospital, Barcelona

08036

Fundació Clínic Per A La Recerca Biomèdica, Barcelona

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

SE5 9RS

King'S College Hospital Nhs Foundation Trust, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT04550936 - Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis | Biotech Hunter | Biotech Hunter